Notice of Proposed Sale · 144
Madrigal Pharmaceuticals, Inc.
MDGLNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Madrigal Pharmaceuticals, Inc.
- Issuer CIK
- 0001157601
- Phone
- 267-824-2827
- Person for whose account securities are to be sold
- William Sibold
- Relationships to issuer
- Officer and Director
- Street
- 1001 Conshohocken State Road
- Street (continued)
- Suite 2-350
- City
- West Conshohocken
- State / country code
- PA
- Postal code
- 19428
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 2,500 | 1,383,700 | 23,055,659 | 07/20/2026 | Nasdaq Stock Market | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza, 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 07/17/2026 | Performance Restricted Stock Unit Grant | Issuer | 2,500 | N | 07/17/2026 | Vesting of Performance Restricted Stock Units |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The sale of shares of common stock reported on this Form 144 represents the sale of shares pursuant to a sell-to-cover transaction in order to satisfy certain tax withholding obligations in connection with the Reporting Owner earning Performance Restricted Stock Units previously granted to the Reporting Owner in September 2023.
Notice signature
- Notice date
- 07/20/2026
- Signed
- /s/ William Sibold
Company context
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.